Valuation: AstraZeneca PLC

Market Cap 241B 208B 195B 178B 334B 23,027B 340B 2,290B 895B 11,531B 904B 884B 38,320B P/E 2026 *
19.9x
P/E 2027 * 17.3x
Enterprise Value 260B 225B 211B 192B 361B 24,875B 367B 2,474B 967B 12,457B 977B 955B 41,395B EV / Sales 2026 *
4.11x
EV / Sales 2027 * 3.78x
Free-Float
96.63%
Yield 2026 *
2.14%
Yield 2027 * 2.27%
1 day-0.79%
1 week-4.14%
Current month-10.26%
1 month-5.18%
3 months-11.56%
6 months-16.10%
Current year-11.81%
1 week 127.75
Extreme 127.752
132.01
1 month 124.91
Extreme 124.91
143.31
Current year 124.91
Extreme 124.91
163
1 year 116.75
Extreme 116.746
163
3 years 104.86
Extreme 104.856
163
5 years 95
Extreme 95
163
10 years 52.7
Extreme 52.7
163
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-4.14% - - 241B
-2.25%-0.47%+72.43%+119.36% 1,052B
-0.66%+0.43%+49.01%+50.11% 627B
-0.54%+1.39%+21.88%+63.83% 441B
-1.99%-3.32%+41.98%+34.08% 349B
-1.05%-2.81%+24.22%+34.67% 287B
-2.12%-3.67%-1.09%+3.11% 241B
-0.63%+1.04%+43.03%+59.10% 224B
-1.19%-3.41%-9.18%-52.41% 202B
+0.16%+3.87%+16.25%+73.27% 172B
Average -0.67%+0.43%+28.73%+42.79% 399.46B
Weighted average by Cap. -0.13%+0.32%+41.31%+62.03%

Financials

2026 *2027 *
Net sales 63.25B 54.63B 51.33B 46.69B 87.77B 6,048B 89.22B 601B 235B 3,029B 237B 232B 10,065B 66.85B 57.74B 54.26B 49.35B 92.77B 6,393B 94.3B 636B 249B 3,201B 251B 246B 10,638B
Net income 12.07B 10.42B 9.8B 8.91B 16.75B 1,154B 17.03B 115B 44.88B 578B 45.32B 44.33B 1,921B 13.72B 11.85B 11.13B 10.12B 19.03B 1,312B 19.35B 130B 51B 657B 51.49B 50.38B 2,183B
Net Debt 19.33B 16.69B 15.69B 14.26B 26.82B 1,848B 27.26B 184B 71.86B 925B 72.56B 70.98B 3,075B 11.66B 10.07B 9.46B 8.61B 16.18B 1,115B 16.45B 111B 43.35B 558B 43.77B 42.82B 1,855B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
14/08/26 CHF 127.75 -0.79% 6
12/08/26 CHF 128.77 -0.26% 47
10/08/26 CHF 129.11 -3.12% 658
07/08/26 CHF 133.27 +0.13% 70
06/08/26 CHF 133.09 +6.55% 136
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
155.26USD
Average target price
211.68USD
Spread / Average Target
+36.34%

Quarterly revenue - Rate of surprise